BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

AI-for-science startup ChemLex raises USD 45M, launching self-driving lab for drug discovery in Singapore

December 5, 2025 | News

ChemLex also signed a memorandum of understanding with the Experimental Drug Development Centre (EDDC)



ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia.

Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and a half years, it has grown to support more than 70 customers worldwide, including six of the world's top ten pharmaceutical companies. This surge reflects a larger industry shift as analysts expect the AI-powered drug discovery market to jump from USD 3.6B in 2024 to nearly USD 50B by 2034.

At the core of ChemLex's platform is a 24/7 autonomous chemistry system that accelerates chemical discovery, making it far more cost-eZicient and significantly more sustainable than traditional laboratory methods. Driving this is an innovative AI-powered, fully automated synthesis line, which runs experiments autonomously, captures data in real-time, and transforms chemical discovery from a stop-start process into a smooth workflow.

The new funding will support the hiring of more hardware and software engineers, as well as chemists in Singapore, enabling the company to serve a broader pipeline of pharmaceutical and materials science projects.

ChemLex also signed a memorandum of understanding with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development. This collaboration seeks to accelerate next-generation small molecule drug discovery through advanced automation.

These initiatives align with the Singapore Economic Development Board's (EDB) eZorts to build a more resilient, innovation-ready life sciences ecosystem.